Suchergebnisse

Canada's drug laws originated and developed in response to racial and political factors rather than reasoned analysis. After tracing the history of the legislation, this paper outlines the current drug offences and enforcement powers. The impact of the Canadian Charter of Rights and Freedoms on drug legislation and enforcement is also considered.

AbstractWhy does the war on drugs continue after 40 years? This article combines theories of policy termination and prospect theory to explain the drug war's persistence. After reviewing the case for termination, the article turns to policy termination theory. As previous case studies have demonstrated, rationality and economic reasoning alone fail to persuade politicians to end existing policies. In the case of the drug war, specific characteristics of the drug policy and the current political environment, as well as typical institutional and bureaucratic constraints, create substantial obstacles to end the drug war. Perceptions of the risks and benefits of drug war termination also create difficulties. The article concludes that a number of factors need to shift before drug war policy termination can take place.

This paper places the concept of the use of coercion in the prevention and treatment of drug abuse within a political context. Coerceive measures are used for control rather than rehabilitation. Whatever the rationale, use of coercion by the state stands in direct opposition to individual liberty.

After describing the intellectual property and regulatory environment for orphan drugs in the United States, this thesis compares the investment decisions in the orphan drug market with the larger pharmaceutical industry. A series of case studies trace the development paths of different orphan products using information collected through the Food and Drug Administration (FDA) Approved Drug Product and Orphan Drug Product Designation Databases. In addition to this analysis, difference-in-differences estimates calculated using annual revenues compare the relative success of different orphan products under the current incentive system. This study finds that partial orphan drugs are associated with larger revenue growth. Lastly, this study proposes several policy prescriptions as alternatives to the current legislation.